Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedincellMDCLF +393.00%77 Cyclically Adjusted PS Ratio is 52.11 as of Jul. 14, 2026, which is 3% below its 10-year median of 53.86. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review. Among 539 Biotechnology companies, Medincell ranks worse than 92.58% on this metric.
The historical rank and industry rank for Medincell's Cyclically Adjusted PS Ratio or its related term are showing as below:
MDCLF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 29.18 Med: 53.86 Max: 87.41
Current: 63.22
During the past 11 years, Medincell's highest Cyclically Adjusted PS Ratio was 87.41. The lowest was 29.18. And the median was 53.86.
MDCLF's Cyclically Adjusted PS Ratio is ranked worse than 92.58% of 539
companies
in the Biotechnology industry
Industry Median: 5.83
vs MDCLF: 63.22
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Medincell's adjusted revenue per share data of for the fiscal year that ended in Mar26 was $0.628. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.66 for the trailing ten years ended in Mar26.
Shiller PE for Stocks: The True Measure of Stock Valuation
Medincell (OTCPK:MDCLF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Medincell Cyclically Adjusted PS Ratio Related Terms
Medincell Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Medincell's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCLF vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Medincell's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Medincell's Cyclically Adjusted PS Ratio falls into.
Medincell Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Medincell's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 52.11 mean?
Medincell (MDCLF) has a Cyclically Adjusted PS Ratio of 52.11 as of Jul. 14, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medincell and its competitors. This is near median its historical median of 53.86. Over the past decade, Medincell's Cyclically Adjusted PS Ratio has ranged from 29.18 to 87.41. According to the industry distribution chart, Medincell ranks #499 out of 539 companies in the Biotechnology industry, placing it in the top 92.6%.
Is Medincell's Cyclically Adjusted PS Ratio too high?
Medincell's current Cyclically Adjusted PS Ratio of 52.11 is near median its 10-year median of 53.86. Over the past 10 years, this metric has ranged from a low of 29.18 to a high of 87.41. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.83. Medincell's value of 52.11 is 793.8% above this industry median. Based on the distribution chart, Medincell ranks #499 out of 539 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #499 out of 539 companies for Cyclically Adjusted PS Ratio. This places Medincell in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.83. Medincell's value of 52.11 is 793.8% above this benchmark. Historically, Medincell's own Cyclically Adjusted PS Ratio has ranged from 29.18 to 87.41 over the past decade. While the company's 10-year median is 53.86 vs. the industry median of 5.83, Medincell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.83, based on 539 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current Cyclically Adjusted PS Ratio of 52.11 is 793.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medincell and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Cyclically Adjusted PS Ratio is 52.11, which is near median its own 10-year median of 53.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Cyclically Adjusted PS Ratio of 52.11. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 52.11, which is near median its 10-year median of 53.86 and 793.8% above the Biotechnology industry median of 5.83. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Medincell (MDCLF), the current Cyclically Adjusted PS Ratio is 52.11 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
Cyclically Adjusted PS Ratio: 52.11 (near median its 10-year median of 53.86)
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
Industry Position: 793.8% above the Biotechnology median (#499 of 539)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
